We are ecstatic to share the news that our CEO, Jeroen Elassaiss-Schaap, has penned an exceptional article that was featured in the 10th edition of Immunowatch by MabDesign, the French biotech&pharma industry association.
The article titled “Accelerating Antibody Development Through Quantitative Systems Pharmacology – The Pembrolizumab Story” provides practical insights into the power of modeling and simulation approaches to revolutionize drug development processes.
By using the success story of Pembrolizumab as a prime example, our CEO showcases how our company’s innovative services can play a pivotal role in accelerating drug development timelines and budgets.
Read the full article in the latest issue of Immunowatch to learn more about how our services can help propel drug development forward. Do you have upcoming R&D transitions and decision points? Let us with a comment, a direct message or an email to explore how our services can support your processes!
